You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 129 No. 9, September 1993 TABLE OF CONTENTS
  Archives
  •  Online Features
  Studies
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

In Vitro Induction of Basal Keratinocyte MY7 Antigen Expression in Cutaneous T-Cell Lymphoma Is Associated With Response to Interferon-Alfa Therapy

Philippe Celerier, MD; Marc Fleischmann, MD; Nicole Basset-Seguin, MD; Laurence Thill, MD; Brigine Bureau, MD; Pierre Litoux, MD; Brigitte Dréno, MD

Arch Dermatol. 1993;129(9):1136-1140.


Abstract

Background
Normal basal cell keratinocytes express an antigen recognized by monoclonal antibody MY7. This expression is lost in cutaneous T-cell lymphoma (CTCL) and may be reinduced under interferon-alfa—2a therapy. We investigated whether similar modulation of MY7 antigen could be obtained in vitro and determined the relationship between in vitro modulation and clinical response.

Subjects
We studied MY7 expression by basal cell keratinocytes in reconstituted skin specimens from 10 patients with CTCL and from skin specimens from five control patients and determined its modulation by interferon-alfa—2a and interleukin 1 using the indirect immunofluorescence technique. Concurrently, clinical examination and in vivo immunologic study on cutaneous biopsy specimens were carried out for these 10 patients before and while receiving interferon-alfa—2a therapy.

Results
In vitro studies showed that in five control specimens MY7 expression by basal cells was constant without modulation by interferon-alfa—2a or interleukin 1 Two of 10 CTCL specimens spontaneously expressed MY7 antigen while an additional five did so after incubation with interferon-alfa—2a and the last three never did.

Conclusion
The three patients with CTCL for whom no MY7 expression was observed in reconstituted skin studies were "poor responders" to interferon-alfa—2a therapy. The five patients with CTCL for whom in vitro MY7 expression was induced by interferon-alfa—2a were responders. For the last two patients, results were variable. Thus, in vitro MY7 antigen is expressed in normal basal cell keratinocytes, absent in CTCL basal cell keratinocytes, but can be induced by interferon-alfa—2a. Moreover this in vitro modulation appears to be possibly correlated with interferon-alfa efficacy in vivo.

(Arch Dermatol. 1993;129:1136-1140)



Author Affiliations

From the Laboratoire d'Immunodermatologie, Clinique de Dermatologie, Hôpital Hôtel-Dieu, Nantes, France (Drs Celerier, Fleischmann, Bureau, Litoux, and Dréno); Laboratoire de Recherche Dermatologique, Service de Dermatologie-Phlebologie, Hôpital Saint Charles, Montpellier, France (Dr Basset-Seguin); and Laboratoire Roche, Neuilly sur Seine, France (Dr Thill).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Keratinocyte-Lymphocyte Interaction in Cutaneous T-Cell Lymphoma: Modulation of Keratinocyte Antigen My7 by a Soluble Factor Produced by T Lymphocytes
Celerier et al.
Arch Dermatol 1997;133:837-840.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.